Aarsand Aasne K, Petersen Per Hyltoft, Sandberg Sverre
Norwegian Porphyria Centre, NAPOS, Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway.
Clin Chem. 2006 Apr;52(4):650-6. doi: 10.1373/clinchem.2005.060772.
Diagnosis of an attack of acute intermittent porphyria (AIP) is based on the demonstration of increased concentrations of porphobilinogen (PBG) and delta-aminolevulinic acid (ALA) in urine, but many AIP patients also have high baseline concentrations in remission. The aim of this study was to estimate the biological variations of ALA, PBG, and porphyrins in healthy individuals and AIP patients to improve interpretation of test results.
Fifteen healthy individuals and 15 AIP patients were included, and biological variations were calculated based on urine samples collected weekly for 10 consecutive weeks. For the AIP patients, long-term variations were also estimated based on 7 samples collected through a 2-year period.
The porphyrin variances were inhomogeneously distributed; biological variations of porphyrins were therefore not calculated. The within-subject biological variations of ALA and PBG were 16%-20% in the short-term settings and for PBG, 25% in the long-term setting, giving reference change values of approximately 50% and 70%, respectively. The probability of detecting a 100% real change in PBG was 97% in the short-term setting and 80% in the long-term setting.
In an AIP patient, a 2-fold increase in PBG, independent of the baseline concentration, will be detected with a probability >80% and is most likely related to the patient's disease and not caused only by analytical and biological variation. When PBG is used in the assessment of AIP-related symptoms, both the PBG concentration in remission and the length of time since the previous sample must be considered.
急性间歇性卟啉病(AIP)发作的诊断基于尿中卟胆原(PBG)和δ-氨基-γ-酮戊酸(ALA)浓度升高的证据,但许多AIP患者在缓解期也有较高的基线浓度。本研究的目的是评估健康个体和AIP患者中ALA、PBG和卟啉的生物学变异,以改善检测结果的解读。
纳入15名健康个体和15名AIP患者,基于连续10周每周采集的尿液样本计算生物学变异。对于AIP患者,还基于2年期间采集的7份样本评估长期变异。
卟啉变异呈不均匀分布;因此未计算卟啉的生物学变异。短期情况下,ALA和PBG的个体内生物学变异为16%-20%,对于PBG,长期情况下为25%,参考变化值分别约为50%和70%。短期情况下检测到PBG实际变化100%的概率为97%,长期情况下为80%。
在AIP患者中,PBG升高2倍,无论基线浓度如何,检测概率>80%,很可能与患者疾病有关,而非仅由分析和生物学变异导致。在评估与AIP相关的症状时使用PBG时,必须同时考虑缓解期的PBG浓度和距上次采样的时间长度。